Track topics on Twitter Track topics that are important to you
Background: The aim was to evaluate the effect of a single intravitreal ranibizumab injection in eyes with non-arteritic anterior ischaemic optic neuropathy. Methods: Four eyes of four patients comprised the study group. In addition to a standard ocular examination, visual field testing and retinal nerve fibre layer thickness analysis were performed prior to injection and one and three months after the injection. Results: Mean time between visual loss and the intravitreal injection was 7.8 days (range, 2-15 days). The mean age of patients was 58.2 years (range, 45-63 years). After a single dose of ranibizumab injection, all patients experienced a visual gain. Mean visual acuity (VA) was 1.15 ± 0.26 logMar before the injection and improved to 0.37 ± 0.09 logMar at the third post-injection month. The mean retinal nerve fibre layer thickness measured with spectral domain optical coherence tomography significantly decreased after the injection in all eyes. No complication related to the injections was observed during the following three months. Conclusion: Intravitreal ranibizumab injection may be a treatment option in eyes with non-arteritic anterior ischaemic optic neuropathy and a short disease history.
Dokuz Eylul University, Department of Ophthalmology, Izmir, Turkey E-mail: firstname.lastname@example.org.
This article was published in the following journal.
Name: Clinical & experimental optometry : journal of the Australian Optometrical Association
To evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and af...
Ranibizumab, a vascular endothelial growth factor-antagonist, is said to be neuroprotective when injected intravitreally in patients with nonarteritic anterior ischemic optic neuropathy (NAION). We ev...
Background: Since 2007, the standard treatment for age related macular degeneration has been intravitreal injection of ranibizumab. However, despite continuous treatment, some patients fail to achieve...
To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy.
The purpose of this study is to make a prospective evaluation of the effect of timolol 0.1% eye gel on short-term intraocular pressure (IOP) after an intravitreal injection (IVI) of ranibizumab.
Title of study: Effects of Ranibizumab to delay or regression non-proliferative diabetic retinopathy(NPDR) with DME assessed by microaneurysm changes: A pilot study Objectives To evaluate...
To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic r...
This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eye...
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.
This open-label, Phase IV prospective, observational study will evaluate patients, who have been diagnosed with Neovascular Age-Related Macular Degeneration and have previously received ei...
Certain percent of the eyes with proliferative diabetic retinopathymay require pars plana vitrectomy (PPV) due to vitreous haemorrhage, proliferative membrane, and tractional retinal detac...
Hemorrhagic necrosis that was first demonstrated in rabbits with a two-step reaction, an initial local (intradermal) or general (intravenous) injection of a priming endotoxin (ENDOTOXINS) followed by a second intravenous endotoxin injection (provoking agent) 24 h later. The acute inflammation damages the small blood vessels. The following intravascular coagulation leads to capillary and venous THROMBOSIS and NECROSIS. Shwartzman phenomenon can also occur in other species with a single injection of a provoking agent, and during infections or pregnancy. Its susceptibility depends on the status of IMMUNE SYSTEM, coagulation, FIBRINOLYSIS, and blood flow.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
Acute conjunctival inflammation in the newborn, usually caused by maternal gonococcal infection. The causative agent is NEISSERIA GONORRHOEAE. The baby's eyes are contaminated during passage through the birth canal.
Gases that irritate the eyes, throat, or skin. Severe lacrimation develops upon irritation of the eyes.
Partial or complete loss of vision in one half of the visual field(s) of one or both eyes. Subtypes include altitudinal hemianopsia, characterized by a visual defect above or below the horizontal meridian of the visual field. Homonymous hemianopsia refers to a visual defect that affects both eyes equally, and occurs either to the left or right of the midline of the visual field. Binasal hemianopsia consists of loss of vision in the nasal hemifields of both eyes. Bitemporal hemianopsia is the bilateral loss of vision in the temporal fields. Quadrantanopsia refers to loss of vision in one quarter of the visual field in one or both eyes.
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...